VolitionRx Limited (NYSE:VNRX) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Scott Powell - IR Cameron Reynolds - CEO Dr. Tom Butera - CEO, Volition Veterinary Terig Hughes - CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Bruce Jackson - The Benchmark Company Nathan Weinstein - Aegis Capital Steven Ralston - Zacks Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to VolitionRx Limited's Second Quarter '22 Earnings Confere ...

© Corporate presentation August 2022 Property of Volition 2022 Slide 1 Forward Looking Statements and Disclaimer Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words su ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (I.R.S. Employer Identification No.) 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of re ...

VolitionRx Limited (NYSE:VNRX) Q1 2022 Results Conference Call May 12, 2022 8:30 AM ET Company Participants Scott Powell - Executive Vice President of Investor Relations Cameron Reynolds - President and Chief Executive Officer Tom Butera - Chief Executive Officer, Volition Veterinary Diagnostics Development Terig Hughes - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Operator Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limited's ...

© Corporate presentation May 2022 Property of Volition 2022 Slide 1 Forward Looking Statements and Disclaimer Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization ...

© Corporate presentation March 2022 Property of Volition 2022 Slide 1 Forward Looking Statements and Disclaimer Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words suc ...

© Corporate presentation March 2022 Property of Volition 2022 Slide 1 Forward Looking Statements and Disclaimer Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words suc ...

VolitionRx Limited (NYSE:VNRX) Q4 2021 Results Conference Call March 31, 2022 8:00 AM ET Company Participants Scott Powell - Executive Vice President of Investor Relations Cameron Reynolds - President and Chief Executive Officer Terig Hughes - Chief Financial Officer Tom Butera - Chief Executive Officer, Volition Veterinary Diagnostics Development Conference Call Participants Ross Osborn - Cantor Fitzgerald Bruce Jackson - The Benchmark Company Nathan Weinstein - Aegis Capital Michael Okunewitch - Maxim Ope ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporatio ...